timothy sykes logo
TXG Stock Jumps As AI Deal And Legal Win Shift Momentum Thumbnail
G Google News

TXG Stock Jumps As AI Deal And Legal Win Shift Momentum

JACK KELLOGG•UPDATED SEP. 24, 2026, 3:02 PM ET
Reviewed by Ellis Hobbsand Fact-checked by Matt Monaco

10x Genomics Inc. stocks have been trading up by 12.23 percent following strong investor optimism over its latest technology developments.

Key Takeaways For TXG Traders

  • A Delaware jury confirmed three 10x Genomics Scale Biosciences patents were infringed by Qiagen’s Parse Biosciences unit, awarding over $4.8M and opening the door to enhanced damages and a potential U.S. injunction.
  • A new partnership with Korea-based Lunit brings AI pathology (Lunit SCOPE IO) into TXG’s Xenium and Atera spatial platforms to sharpen tumor characterization and oncology biomarker discovery.
  • RBC launched coverage of TXG at Sector Perform with a $70 target, praising spatial biology leadership but flagging flat single-cell growth that drags on long-term revenue expansion.
  • UBS and Deutsche Bank now sit in the $68–$70 target range, while TXG’s Street consensus hovers near $52 and the stock holds an average Overweight rating.
  • Recent insider selling from the CFO and a director, totaling more than $4M, adds a sentiment headwind even as both insiders keep large TXG stakes.

Candlestick Chart

Live Update At 15:02:26 EDT: On Thursday, September 24, 2026 10x Genomics Inc. stock [NASDAQ: TXG] is trending up by 12.23%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

TXG has been trading like a momentum name, not a sleepy lab supplier. The stock has ripped from a close near $62 in late August to $84.91 on 2026/09/24. That’s more than a 35% move in under a month, with the latest session opening at $75.50 and powering to an intraday high above $85 before settling just under that level. For short-term traders, TXG is clearly in an aggressive uptrend.

Intraday, the 5‑minute tape shows steady higher lows through the afternoon, with TXG grinding from the low $80s around midday to the mid‑$80s into the close. This is classic trend-following action: dips keep getting bought, and sellers are forced to cover into strength.

More Breaking News

Fundamentally, 10x Genomics is still a high‑growth, money‑losing platform story. TXG posted about $151M in quarterly revenue, with gross margin around 70%, but operating income came in at roughly -$23M and net income at about -$18M. Key ratios confirm the picture: strong top‑line expansion over several years, but negative returns on assets and equity, and no PE because earnings are still red. Low debt and a current ratio above 5 give TXG plenty of runway, but traders are clearly paying up for future optionality, not present profits.

Why Traders Are Watching TXG Right Now

TXG is sitting at the intersection of three hot themes: spatial biology, AI in healthcare, and IP-heavy biotech tools. That’s why the tape is so active, even with the company still burning cash.

First, the patent win against Qiagen’s Parse Biosciences unit is more than a $4.8M check. A Delaware jury validated three Scale Biosciences patents and tied damages to a 14% royalty on U.S. sales of Evercode Whole Transcriptome from 2021 to mid‑2026. TXG plans to chase enhanced damages, attorneys’ fees, and a possible U.S. injunction. For traders, the real story is competitive pressure: if a rival’s key single‑cell product is limited or taxed by royalties, TXG’s franchise looks stronger and pricing power more defendable.

Second, the Lunit deal drops AI gas on TXG’s spatial fire. Integrating Lunit SCOPE IO — an AI pathology engine — into 10x Genomics’ Xenium and Atera platforms pulls together standard H&E images with spatial molecular data. That’s exactly what pharma and biotech teams want for antibody‑drug conjugate projects and immunotherapy response work. Even without disclosed dollars, this kind of workflow integration makes TXG’s ecosystem stickier and harder to rip out once a lab standardizes around it.

On the Street, coverage is catching up to the move. RBC sees TXG as a Sector Perform with a $70 target, calling out more than 60% share in spatial profiling and strong double‑digit growth there, but warning that single‑cell revenue may run flat for five years. UBS sits at Neutral with $68, and Deutsche Bank just hiked its TXG target to $70 from $40 while staying Hold. Put together, traders are looking at a name trading well above the consensus near $52, fed by momentum and story, while analysts are still lukewarm on near‑term upside. Add in sizable insider sales from the CFO and a director, and you have a crowded long with just enough doubt to keep volatility high.

Conclusion

TXG is a classic story-stock setup: strong technology, clear sector tailwinds, and very real execution and valuation risks. The jury win against Qiagen’s Parse Biosciences unit reinforces 10x Genomics’ IP moat in single‑cell analysis, and any future injunction or enhanced damages would only deepen that edge. The Lunit partnership pushes TXG deeper into AI‑powered oncology workflows, exactly where pharma money is flowing. Those are the kinds of catalysts that can keep traders piling into strength.

At the same time, the core financials remind everyone this is still a loss‑making growth engine. TXG is running 70% gross margins on more than $600M in annualized revenue, but operating losses and negative returns show the business is still in build‑out mode. Analysts acknowledge the promise, yet RBC, UBS, and Deutsche Bank all stop short of a full‑throttle bull call, anchoring targets around $68–$70 and highlighting slowing single‑cell growth as a real drag.

Layer on multi‑million‑dollar insider sales and a chart that’s gone vertical in a few weeks, and TXG becomes exactly the kind of name active traders study hard. As Tim Sykes likes to say, “Patterns repeat, but only prepared traders profit from them.” As millionaire penny stock trader and teacher Tim Sykes, says, “The goal is not to win every trade but to protect your capital and keep moving forward.”. For TXG, that means mapping the chart against these IP wins, AI deals, and cautious analyst notes, then trading the volatility — with tight risk and even tighter discipline. This content is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”